You are viewing: Latin America Nuclear Medicine Market analysis
Part of: Nuclear Medicine Market (Global)

The Latin America Nuclear Medicine Market was valued at $357.6 Million in 2025 and projected to reach to $513.9 Million by 2030, representing a compound annual growth rate of 7.5%. The Latin America nuclear medicine market is positioned for sustained growth through 2030, with expanding healthcare budgets and rising awareness of nuclear medicine's diagnostic capabilities.

Latin America Nuclear Medicine Market Trends and Insights

  • Latin America's nuclear medicine sector is experiencing steady growth driven by increasing healthcare investments, rising prevalence of chronic diseases, and expanding diagnostic imaging infrastructure across the region.
  • In 2025, Latin America accounts for a growing share of diagnostic and therapeutic nuclear medicine applications, with demand concentrated in major economies including Brazil, Mexico, and Argentina. Latin America's nuclear medicine market growth is supported by improving reimbursement policies, greater adoption of positron emission tomography (PET) and single-photon emission computed tomography (SPECT) technologies, and enhanced access to radiopharmaceuticals.
  • Between 2025 and 2030, Latin America is expected to see accelerated deployment of nuclear medicine centers in both urban and emerging healthcare markets.
  • The region's market expansion reflects broader trends in precision medicine and personalized diagnostics, positioning Latin America as an increasingly important market within the global nuclear medicine landscape..

Key Market Statistics

  • CAGR (2025-2030) 7.5% CAGR
  • Market Size, 2025 ~USD 357.6 Million
  • Forecast, 2030 ~USD 513.9 Million
  • Geography Latin America

Latin America Nuclear Medicine Market Overview

Steady Regional Growth :

Latin America's nuclear medicine market is expanding at a CAGR of 7.5%, driven by increasing healthcare investments and modernization of diagnostic imaging infrastructure across the region.

Rising Chronic Disease Burden :

Growing prevalence of cancer, cardiovascular diseases, and metabolic disorders in Latin America is fueling demand for advanced nuclear medicine diagnostics and therapeutic applications.

Brazil's Market Leadership :

Brazil dominates the Latin American nuclear medicine market with USD 395.7 million in 2025, representing the largest healthcare economy and investment in nuclear imaging technologies in the region.

Infrastructure Expansion :

Increasing establishment of nuclear medicine centers and PET/CT facilities across major Latin American cities is improving patient access to advanced diagnostic and therapeutic nuclear medicine services.

Latin America Nuclear Medicine Market Dynamics

  • Key drivers include the increasing incidence of chronic diseases, government healthcare initiatives, and private sector investments in medical imaging infrastructure.
  • Brazil and Mexico are leading market contributors, with growing adoption of PET/CT and SPECT technologies. Latin America's nuclear medicine sector will benefit from technological advancements, improved reimbursement policies, and enhanced regulatory frameworks.
  • However, challenges such as high equipment costs, limited radiopharmaceutical availability, and workforce training gaps require strategic attention.
  • Regional partnerships and collaborations with global nuclear medicine providers are expected to accelerate market penetration and service expansion across the region..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • SANOFI
  • NOVARTIS
  • Pfizer Inc.

    Key Takeaways

    • Latin America's nuclear medicine market is valued at USD 357.6 million in 2025 and will reach USD 513.9 million by 2030, growing at 7.5% CAGR.
    • Latin America is experiencing increased adoption of PET and SPECT imaging technologies driven by healthcare infrastructure modernization and rising chronic disease prevalence.
    • Latin America's market growth is supported by improving reimbursement frameworks and expanding radiopharmaceutical availability across major regional economies.
    • Latin America represents a strategic growth opportunity within the global nuclear medicine market, with significant expansion potential in emerging healthcare segments through 2030.

    Nuclear Medicine Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment THERAPEUTIC NUCLEAR MEDICINE (Type)
    Forecast Period 2025–2039
    Growth Rate CAGR of 15.1% from 2025 to 2039
    Largest Segment DIAGNOSTIC PROCEDURES (Procedure)
    Market Size Base Year (Billions) ~USD 10.4 (2025)
    Revenue Forecast (Billions) ~USD 21.01 (2039)
    Segments Covered Type, Application, Procedure, End User

    Latin America Nuclear Medicine Market Report Segmentation

    4 segment dimensions are covered across the global market.

    By Type

    • Alpha Emitters
    • Beta Emitters
    • Bone Metastasis
    • Bone Scans
    • Brachytherapy Isotopes
    • Cardiology
    • Cs-131
    • Diagnostic Nuclear Medicine
    • Endocrine Tumors
    • F-18
    • Ga-67
    • I-123
    • I-125
    • I-131
    • Ir-192
    • Lu-177
    • Lymphoma
    • Neurology
    • Oncology
    • Other Beta Emitters
    • Other Brachytherapy Isotopes
    • Other Pet Applications
    • Other Pet Radiopharmaceuticals
    • Other Spect Applications
    • Other Spect Radiopharmaceuticals
    • Other Therapeutic Applications
    • Pd-103
    • Pet Applications
    • Pet Procedures
    • Pet Radiopharmaceuticals
    • Pulmonary Scans
    • Ra-223
    • Rb-82
    • Sm-153
    • Spect Applications
    • Spect Procedures
    • Spect Radiopharmaceuticals
    • Tc-99M
    • Therapeutic Nuclear Medicine
    • Thyroid
    • Tl-201
    • Y-90

    By Application

    • Diagnostic Applications
    • Therapeutic Applications

    By Procedure

    • Diagnostic Procedures
    • Therapeutic Procedures

    By End User

    • Academic & Research Institutes
    • Diagnostic & Imaging Centers
    • Hospitals
    • Other End Users

    Target Audience

    • Medical Device Manufacturers : Need Latin America-specific market data to develop regional product strategies, pricing models, and distribution partnerships for nuclear medicine equipment and imaging systems.
    • Healthcare Investors & PE Firms : Require detailed market sizing and growth forecasts for Latin America to evaluate investment opportunities in nuclear medicine centers, diagnostic imaging networks, and healthcare infrastructure.
    • Pharmaceutical & Radiopharmaceutical Companies : Need regional market insights to assess demand for radiopharmaceuticals, plan manufacturing capacity, and develop market penetration strategies across Latin American countries.
    • Hospital & Diagnostic Center Operators : Require market intelligence on regional trends, patient demand, and competitive positioning to guide capital investments in nuclear medicine capabilities and service expansion.
    • Healthcare Consultants & Strategy Firms : Need comprehensive Latin America market data to support client advisory work, feasibility studies, and strategic planning for healthcare organizations entering or expanding in the region.

    Key Companies in the Latin America Nuclear Medicine Market

    CompanyHQOwnershipStrongest segments
    BIOMERIEUX S.A.FrancePublic CompanySPECT,PET,Beta Emitters,
    CARL ZEISS AGGermanyPublic CompanyPET (F-18),SPECT (Tc-99m),
    ATS AUTOMATION TOOLING SYSTEMS INCCanadaPublic CompanySPECT,PET,Brachytherapy,
    BRUKER CORPORATIONUnited StatesPublic CompanyPET,SPECT,Beta Emitters,
    SHIMADZU CORPORATIONJapanPublic CompanyPET (F-18),SPECT (Tc-99m),Alpha Emitters,
    VARIAN MEDICAL SYSTEMS, INCUnited StatesPrivate CompanyBrachytherapy,Linear Accelerators,Software Solutions,
    LEONI AGGermanyPrivate CompanyPET Systems,SPECT Systems,Beta Emitters,
    PFIZERUnited StatesPublic CompanyPET (F-18),Beta Emitters (Y-90, Lu-177),SPECT (Tc-99m),
    ELEKTA ABSwedenPublic CompanyBrachytherapy,Linear Accelerators,Stereotactic Radiosurgery,
    NOVARTIS AGSwitzerlandPublic CompanyBeta Emitters,SPECT,Alpha Emitters,
    LANTHEUS HOLDINGS, INC.United StatesPublic CompanyPET,SPECT,Beta Emitters,
    GE HEALTHCAREUnited StatesPublic CompanySPECT,PET,Brachytherapy,
    TELIX PHARMACEUTICALS LIMITEDAustraliaPublic CompanyPET Imaging,Therapeutics,Manufacturing Solutions,
    SIEMENS HEALTHINEERSGermanyPublic CompanyPET,SPECT,Beta Emitters,
    CHINA ISOTOPE & RADIATION CORPORATIONChinaPublic CompanySPECT,PET,Beta Emitters,
    BAYER AGGermanyPublic CompanySPECT,PET,Alpha Emitters,
    CARDINAL HEALTHUnited StatesPublic CompanySPECT,PET,Beta Emitters,

    BIOMERIEUX S.A.

    bioMérieux S.A. is a French public company founded in 1963 that employs 14,894 people. The company operates in the diagnostics and life sciences sector.

    CARL ZEISS AG

    Carl Zeiss AG is a German public company founded in 1846 with 5,798 employees. The company specializes in optical systems and precision instruments.

    ATS AUTOMATION TOOLING SYSTEMS INC

    ATS Automation Tooling Systems Inc. is a Canadian public company founded in 1978 with 7,000 employees. The company provides automation and tooling solutions.

    BRUKER CORPORATION

    Bruker Corporation is a United States public company founded in 1960 with 11,085 employees. The company manufactures scientific instruments and analytical solutions.

    SHIMADZU CORPORATION

    Shimadzu Corporation is a Japanese public company founded in 1875 with 14,649 employees. The company manufactures analytical and scientific instruments.

    VARIAN MEDICAL SYSTEMS, INC

    Varian Medical Systems, Inc. is a United States private company founded in 1948 with 10,000 employees. The company specializes in medical devices and radiation oncology solutions.

    LEONI AG

    Leoni AG is a German private company founded in 1569 with 95,090 employees. The company manufactures cables, wiring systems, and related products.

    PFIZER

    Pfizer is a United States public company founded in 1849 with 75,000 employees. The company is a major pharmaceutical manufacturer and developer.

    ELEKTA AB

    Elekta AB is a Swedish public company founded in 1972 with 4,353 employees. The company specializes in radiation therapy and radiosurgery solutions.

    NOVARTIS AG

    Novartis AG is a Swiss public company founded in 1996 with 75,267 employees. The company is a leading pharmaceutical and healthcare company.

    LANTHEUS HOLDINGS, INC.

    Lantheus Holdings, Inc. is a United States public company founded in 1956 with 1,193 employees. The company develops diagnostic imaging agents and radiopharmaceuticals.

    GE HEALTHCARE

    GE Healthcare is a United States public company founded in 2022 with 54,000 employees. The company provides medical imaging, diagnostics, and healthcare IT solutions.

    TELIX PHARMACEUTICALS LIMITED

    Telix Pharmaceuticals Limited is an Australian public company founded in 2015 with 1,152 employees. The company develops diagnostic and therapeutic radiopharmaceuticals.

    SIEMENS HEALTHINEERS

    Siemens Healthineers is a German public company founded in 1896 with 72,369 employees. The company provides medical imaging, diagnostics, and healthcare solutions.

    CHINA ISOTOPE & RADIATION CORPORATION

    China Isotope & Radiation Corporation is a Chinese public company founded in 1983 with 3,578 employees. The company operates in the isotope and radiation sector.

    BAYER AG

    Bayer AG is a German public company founded in 1863 with 87,757 employees. The company operates in pharmaceuticals, crop science, and consumer health.

    CARDINAL HEALTH

    Cardinal Health is a United States public company founded in 1979 with 55,392 employees. The company is a healthcare services and products distributor.

    Latin America vs. other regions

    HowLatin America compares to the other 3 regional blocs covered in this market.

    Global
    ~USD 21.01 Million · 15.1% wtd CAGR ·
    North America
    ~USD 5801.6 Million · 13.6% wtd CAGR ·
    Europe
    ~USD 3132.3 Million · 14.6% wtd CAGR ·
    Asia Pacific
    ~USD 2850 Million · 15.9% wtd CAGR ·
    Middle East & Africa
    ~USD 474.4 Million · 11% wtd CAGR ·

    Countries within Latin America - compare and drill down

    Country2025 size (native)
    BrazilUSD 395.7 Million
    MexicoUSD 210 Million

    Country market size visualization

    Brazil
    USD 395.7 Million
    Mexico
    USD 210 Million

    Reasons to Buy this Report

    • Regional Market Sizing & Forecasts : Obtain precise market valuations for Latin America (USD 357.6M in 2025) with detailed 5-year projections to 2030, enabling accurate business planning and investment decisions specific to the region.
    • Country-Level Insights : Access granular data on Brazil, Mexico, and other Latin American markets to identify high-growth opportunities and tailor market entry or expansion strategies by country.
    • Competitive Landscape Analysis : Understand regional competitive dynamics, key players, and market consolidation trends specific to Latin America's nuclear medicine sector to inform strategic positioning.
    • Growth Driver Identification : Analyze region-specific factors including healthcare infrastructure development, regulatory changes, and disease prevalence patterns driving nuclear medicine adoption across Latin America.
    • Investment & Partnership Opportunities : Identify high-potential markets and segments within Latin America for partnerships, acquisitions, or new facility development based on comprehensive regional market intelligence.

    Frequently asked questions

    What is the current size of the nuclear medicine market in Latin America?

    The Latin America nuclear medicine market is valued at USD 357.6 million in 2025 and is expected to grow to USD 513.9 million by 2030.

    What is the projected growth rate for nuclear medicine in Latin America?

    Latin America's nuclear medicine market is projected to grow at a compound annual growth rate (CAGR) of 7.5% from 2025 to 2030.

    Which countries drive the nuclear medicine market in Latin America?

    Brazil, Mexico, and Argentina are the primary markets driving nuclear medicine demand in Latin America, accounting for the majority of regional diagnostic and therapeutic applications.

    What factors are driving growth in Latin America's nuclear medicine market?

    Latin America's nuclear medicine market growth is driven by increasing healthcare investments, rising chronic disease prevalence, expanding diagnostic imaging infrastructure, improved reimbursement policies, and greater adoption of advanced imaging technologies.

    How does Latin America's nuclear medicine market compare to global trends?

    While Latin America's 7.5% CAGR is lower than the global 15.1% CAGR, the region represents a significant emerging market with substantial growth potential as healthcare infrastructure and access to nuclear medicine services continue to expand.

    RESEARCH METHODOLOGY

    This study involved four major activities in estimating the size of the nuclear medicine market. Exhaustive secondary research was done to collect information on the market, peer market, and parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across value chains through primary research. The bottom-up approach was employed to estimate the overall market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and sub-segments.

    Secondary Research

    The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Some non-exclusive secondary sources include the Organisation for Economic Co-operation and Development (OECD), European Association of Nuclear Medicine (EANM), National Institutes of Health (NIH), World Nuclear Association (WNA), International Atomic Energy Agency (IAEA), Nuclear Regulatory Commission (NRC), Society of Nuclear Medicine and Molecular Imaging (SNMMI), Nuclear Energy Agency (NEA), Australian Nuclear Science and Technology Organisation (ANSTO), Annual Reports, SEC Filings, Investor Presentations, Journals, Publications from Government Sources and Professional Associations, Expert Interviews, and MarketsandMarkets Analysis.

    Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the clinical decision support system market. It was also used to obtain important information about the key players and market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

    Primary Research

    In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the clinical decision support system market. The primary sources from the demand side included industry experts, consultants, healthcare providers, hospital administration, and government bodies. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and key market dynamics.

    Breakdown of Primary Interviews

    Nuclear Medicine Market Size, and Share

    Note 1: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

    Note 2: Tiers of companies are defined on the basis of their total revenue in 2022; Tier 1: >USD 1 billion, Tier 2: USD 500 million to USD 1 billion, and Tier 3: <USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Report Metric

    Details

    Siemens Healthineers

    Sr.Sales Manager

    Curium

    General Manager

    Cardinal Health

    Product Sales Specialist

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the total size of the nuclear medicine market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    • The key players in the industry and markets have been identified through extensive secondary research
    • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes
    • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

    Data Triangulation

    After arriving at the overall market size—using the market size estimation processes as explained above—the market was split into several segments and sub-segments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides, in the provider, payer, and other industries.

    Market Definition

    Radiopharmaceuticals are drugs that contain radionuclide-emitting ionizing radiation and are used in nuclear imaging to diagnose and treat diseases. The nuclear medicine market is bifurcated into diagnostic and therapeutic segments. Radiopharmaceuticals in the diagnostics market are categorized as SPECT and PET, while radiopharmaceuticals in the therapeutics market are categorized as beta emitters, alpha emitters, and brachytherapy isotopes.

    Key Stakeholders

    • Senior Management
    • Finance/Procurement Department
    • R&D Department

    Report Objectives

    • To define, describe, and forecast the nuclear medicine market on the basis of type, application, procedure volume,end user, and region
    • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
    • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to four main regions—North America, Europe, the Asia Pacific, and the Rest of the World (RoW)
    • To profile the key players and comprehensively analyze their market shares and core competencies
    • To track and analyze competitive developments such as partnerships, collaborations, agreements, product approval & enhancements, expansions, and acquisitions in the nuclear medicine market

    Available Customizations

    MarketsandMarkets offers the following customizations for this market report:

    • Additional country-level analysis of the nuclear medicine market.
    • Profiling of additional market players (up to 3)

    Get the Full Nuclear Medicine Market Report

    Full forecast, segment splits, and company analysis for all Nuclear Medicine Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status